Gelesis Holdings, Inc.
Gelesis Holdings, Inc. (GLS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GLS · as of Jun 9, 2026
Key Statistics
Explore Gelesis Holdings, Inc. Data
gls stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 40.0%
Competitors & Peers
gls competitorsGLS
AMTI
AXLA
CYCC
HURA
KRROStock Performance
Full HistoryAbout Gelesis Holdings, Inc.
Gelesis Holdings, Inc. Gelesis Holdings Inc. is a biopharmaceutical company actively marketing products, dedicated to creating biomimetic solutions that target the underlying causes of obesity and chronic gastrointestinal c…
what is gelesis holdings, inc. · gls stock overview · gelesis holdings, inc. company profile · who is gelesis holdings, inc. ceo · gls NYSE · gelesis holdings, inc. headquarters · gelesis holdings, inc. business segments
About Stock Overview & Key Data
Gelesis Holdings, Inc. (GLS) is a Healthcare company in the Biotechnology industry, listed on NYSE since Jan 14, 2022. As of the latest trading session, GLS stock price is $0.16, with a market capitalization of $11.6M. The stock has returned -96.44% over the past 12 months and -69.50% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Gelesis Holdings, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2022, Gelesis Holdings, Inc. reported revenue of $25.8M and net income of -$55.8M. For detailed data — including Gelesis Holdings, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Gelesis Holdings, Inc. (GLS) stock price is $0.16. The stock is traded on NYSE under the ticker symbol GLS. The 52-week range is $0.01 – $5.67.